Neoadjuvant chemotherapy in muscle-invasive bladder cancer
Wang Chunyang
Wang Zhongxin
Fu Weij un
Abstract：Muscle-invasive bladder cancer (MIBC)refers to the bladder cancer with clinical stage of cT2-cT4a .MIBC is characterized by the fast progress,apt to recurrence,likely to distant metastasis,high malignancy and high mortality.At present,radical cystectomy (RC)plus pelvic lymph node dissection (PLND)is considered the standard treatment for MIBC. However,the 5-year survival rate of patients with MIBC remains low,ranging from 27%-67%.In order to improve the on-cological outcome,guidelines recommend cisplatin-based neoadjuvant chemotherapy for the treatment of patients with MI-BC.Neoadjuvant chemotherapy could improve the 5-year survival of MIBC.This article reviews the optimal chemotherapy regimens,current status and future issues of the neoadjuvant chemotherapy.
Keywords：bladder cancermuscle-invasive bladder cancerneoadjuvant chemotherapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 189-192 )